Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of MBX 1416 in Healthy Volunteers
NCT06036784Phase 1Completed
- Sponsor
- MBX Biosciences, Inc.
- Start
- Sep 2023
- Primary completion
- Nov 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of imapextide in post-bariatric hypoglycemia (PBH) (4 arms), sponsored by MBX Biosciences, Inc. Primary endpoints: Number of participants with adverse events (AEs), Serious Adverse Events (SAEs) and Maximum Plasma Concentration (Cmax). Started Sep 2023; status: completed.
02
Drugs
imapextide
03
Conditions
post-bariatric hypoglycemia (PBH)
Beyond the preview
Go deeper on NCT06036784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06036784.